Takeda Pharmaceutical Co Ltd (TAK)
13.28
+0.08
(+0.64%)
USD |
NYSE |
May 02, 16:00
13.28
0.00 (0.00%)
After-Hours: 16:16
Takeda Pharmaceutical Net Income (TTM): 1.271B for Dec. 31, 2023
Net Income (TTM) Chart
Historical Net Income (TTM) Data
| Date | Value |
|---|---|
| December 31, 2023 | 1.271B |
| September 30, 2023 | 1.400B |
| June 30, 2023 | 2.179B |
| March 31, 2023 | 2.338B |
| December 31, 2022 | 2.005B |
| September 30, 2022 | 1.668B |
| June 30, 2022 | 1.638B |
| March 31, 2022 | 2.086B |
| December 31, 2021 | 4.045B |
| September 30, 2021 | 4.421B |
| June 30, 2021 | 4.041B |
| March 31, 2021 | 3.550B |
| December 31, 2020 | 1.705B |
| September 30, 2020 | 524.31M |
| June 30, 2020 | 1.118B |
| March 31, 2020 | 414.73M |
| December 31, 2019 | 133.36M |
| September 30, 2019 | 764.66M |
| June 30, 2019 | 567.68M |
| March 31, 2019 | 1.221B |
| December 31, 2018 | 988.47M |
| September 30, 2018 | 1.256B |
| June 30, 2018 | 1.075B |
| March 31, 2018 | 1.660B |
| December 31, 2017 | 1.713B |
| Date | Value |
|---|---|
| September 30, 2017 | 1.489B |
| June 30, 2017 | 1.478B |
| March 31, 2017 | 1.097B |
| December 31, 2016 | 1.252B |
| September 30, 2016 | 1.361B |
| June 30, 2016 | 1.363B |
| March 31, 2016 | 643.85M |
| December 31, 2015 | -958.34M |
| September 30, 2015 | -1.286B |
| June 30, 2015 | -1.260B |
| March 31, 2015 | -1.136B |
| December 31, 2014 | 497.98M |
| September 30, 2014 | 880.89M |
| June 30, 2014 | 1.044B |
| March 31, 2014 | 1.081B |
| December 31, 2013 | 1.445B |
| September 30, 2013 | 1.137B |
| June 30, 2013 | 1.114B |
| March 31, 2013 | 1.843B |
| December 31, 2012 | 1.278B |
| September 30, 2012 | 1.365B |
| June 30, 2012 | 1.728B |
| March 31, 2012 | 1.562B |
| December 31, 2011 | 2.416B |
| September 30, 2011 | 2.956B |
Net Income Definition
Net Income is the total amount of profit earned by a company. This metric boils down to the overall profit that is left from the revenue that a company receives after taking out various operational line items like cost of goods sold, income tax expense, SG&A expense, etc. Eventually, all companies would want to have a consistent positive and growing net income, so that this can be used for various purposes like reinvesting into the company, paying off debt, and potentially paying out dividends to shareholders.
Net Income (TTM) Range, Past 5 Years
133.36M
Minimum
Dec 2019
4.421B
Maximum
Sep 2021
1.888B
Average
1.668B
Median
Sep 2022
Net Income (TTM) Benchmarks
| Hoya Corp | 1.194B |
| Astellas Pharma Inc | -19.58M |
| Nxera Pharma Co Ltd | -50.91M |
| PeptiDream Inc | 20.76M |
| Stemcell Holdings Inc | 3.099M |